Hubei Biocause Pharmaceutical Co., Ltd. logo

Hubei Biocause Pharmaceutical Co., Ltd. (000627)

Market Closed
7 Feb, 06:57
XSHE XSHE
¥
3. 97
+0.09
+2.32%
¥
19.61B Market Cap
- P/E Ratio
0.44% Div Yield
211,021,646 Volume
- Eps
¥ 3.88
Previous Close
Day Range
3.79 4.06
Year Range
1.61 5.42

Summary

000627 closed Friday higher at ¥3.97, an increase of 2.32% from Thursday's close, completing a monthly decrease of -15.17% or ¥0.71. Over the past 12 months, 000627 stock lost -15.17%.
000627 is not paying dividends to its shareholders.
The last earnings report, released on May 24, 2024, missed the consensus estimates by -0.02%. On average, the company has fell short of earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on XSHE (CNY).
Want to track 000627 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

000627 Chart

Hubei Biocause Pharmaceutical Co., Ltd. (000627) FAQ

What is the stock price today?

The current price is ¥3.97.

On which exchange is it traded?

Hubei Biocause Pharmaceutical Co., Ltd. is listed on XSHE.

What is its stock symbol?

The ticker symbol is 000627.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 19.61B.

Has Hubei Biocause Pharmaceutical Co., Ltd. ever had a stock split?

No, there has never been a stock split.

Hubei Biocause Pharmaceutical Co., Ltd. Profile

Insurance - Life Industry
Financial Services Sector
Ms. Wenxia Zhou CEO
XSHE Exchange
CNE000000F48 ISIN
CN Country
1,765 Employees
- Last Dividend
12 Apr 2010 Last Split
12 Nov 1996 IPO Date

Overview

Hubei Biocause Pharmaceutical Co., Ltd. is a multifaceted enterprise based in Jingmen, China, with a primary focus on providing life and motor insurance products to the Chinese market. Beyond insurance, the company has diversified interests in the pharmaceutical, chemical, and new energy fuel sectors. The firm is engaged in both research and production activities across a variety of products and services. With an international footprint, Hubei Biocause Pharmaceutical exports its products to approximately 85 countries worldwide, including the United States and the European Union, showcasing its global reach and the diverse markets it serves.

Products and Services

  • Life and Motor Insurance: Offering comprehensive insurance solutions tailored to meet the needs of individuals and families in China, the company provides essential financial protection against life's uncertainties.
  • Pharmaceuticals: The company is actively involved in contract research and the production of APIs (Active Pharmaceutical Ingredients), intermediates, and various formulations such as tablets, granules, and capsules. These pharmaceutical products are designed to meet rigorous health and safety standards, addressing different therapeutic needs.
  • Chemicals: Hubei Biocause Pharmaceutical provides a range of chemicals for industrial applications. This includes the manufacture of dimethyl ether gas, used as an aerosol propellant or a liquefied gas fuel, and a-chloropropionyl chloride, a key intermediate in organic synthesis.
  • New Energy Fuels: In line with global sustainability efforts, the company invests in the new energy fuel sector, focusing on the development and production of cleaner, more efficient fuel alternatives to traditional fossil fuels.

Contact Information

Address: 122-132 Yangwan Road, Jingmen, China, 448000
Phone: 86 27 6565 1730